This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
HEXO Catches Eye: Stock Jumps 6.6%
by Zacks Equity Research
HEXO saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Here is Why Growth Investors Should Buy Bio-Rad (BIO) Now
by Zacks Equity Research
Bio-Rad (BIO) could produce exceptional returns because of its solid growth attributes.
Will Bio-Rad Laboratories Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Bio-Rad Laboratories.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Bio-Rad (BIO) seeing solid revenue growth in geographies like Americas and Asia Pacific buoys optimism.
What Makes Bio-Rad (BIO) a New Strong Buy Stock
by Zacks Equity Research
Bio-Rad (BIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bio-Rad (BIO) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Bio-Rad's (BIO) solid revenue growth in geographies like Americas and Asia Pacific in Q4 buoys optimism.
Bio-Rad Laboratories (BIO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
by Zacks Equity Research
Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.
Luminex Buys MilliporeSigma's Flow Cytometry Unit for $75M
by Zacks Equity Research
The recent buyout is likely to contribute $40-$50 million to Luminex's (LMNX) revenues in 2019.
Bio-Rad (BIO) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bio-Rad Clinches USDA Contract, Boosts Life Science Segment
by Zacks Equity Research
Bio-Rad (BIO) adopts initiatives to boost Life Science unit.
Bio-Rad (BIO) Earnings Miss Estimates in Q3, Revenues Beat
by Zacks Equity Research
Bio-Rad's (BIO) solid revenue growth in geographies like North America, China and Asia Pacific in Q3 buoys optimism.
Bio-Rad Laboratories (BIO) Q3 Earnings Lag Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of -21.55% and 1.08%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?
by Zacks Equity Research
McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.
Bio-Techne Partners Micropoint Bioscience, Expands in China
by Zacks Equity Research
Bio-Techne (TECH) believes that its Chinese collaboration is a strategic fit as it will solidify the integration of microfluidic technology for more apt POC diagnostic tools for precision medicine.
What's in Store for Cerner (CERN) This Earnings Season?
by Zacks Equity Research
Cerner's (CERN) third-quarter 2018 results are likely to be hurt by soft segmental results; guidance promising.
Will Instruments Drive Intuitive Surgical (ISRG) Q3 Earnings?
by Zacks Equity Research
Strong prospects in the Instruments and Accessories segment to drive Intuitive Surgical???s (ISRG) top line in the third quarter of 2018.
Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Solid prospects in the Oncology segment to boost Varian Medical's (VAR) top-line performance in the fourth quarter of fiscal 2018.
What's in Store for Express Scripts' (ESRX) Q3 Earnings?
by Zacks Equity Research
Express Scripts (ESRX) likely to see soft PBM revenues in the third quarter of 2018; guidance strong.
Bio-Rad (BIO) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Steer Clear of AmerisourceBergen Now (Revised)
by Zacks Equity Research
AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.
Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes
by Zacks Equity Research
Bio-Rad (BIO) actively expands portfolio for blood typing market; declining gross margin a concern.
Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.
Bio-Rad Laboratories (BIO) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 21.48% and 4.51%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?